Reviva Pharmaceuticals Valuation
| RVPHW Stock | USD 0.14 0.01 7.69% |
Reviva Pharmaceuticals seems to be undervalued based on Macroaxis valuation methodology. Our model determines the value of Reviva Pharmaceuticals from analyzing the company fundamentals such as Cash And Equivalents of 353.26 K, return on equity of -17.95, and EBITDA of (39.5 T) as well as examining its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Reviva Pharmaceuticals' price fluctuation is out of control at this time. Calculation of the real value of Reviva Pharmaceuticals is based on 3 months time horizon. Increasing Reviva Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Reviva stock is determined by what a typical buyer is willing to pay for full or partial control of Reviva Pharmaceuticals Holdings. Since Reviva Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Reviva Stock. However, Reviva Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.14 | Real 0.19 | Hype 0.15 | Naive 0.19 |
The intrinsic value of Reviva Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Reviva Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Reviva Pharmaceuticals Holdings helps investors to forecast how Reviva stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Reviva Pharmaceuticals more accurately as focusing exclusively on Reviva Pharmaceuticals' fundamentals will not take into account other important factors: Reviva Pharmaceuticals Total Value Analysis
Reviva Pharmaceuticals Holdings is at this time forecasted to have takeover price of 0 with market capitalization of 85.81 M, debt of 17.98 M, and cash on hands of 353.26 K. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Reviva Pharmaceuticals fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
0 | 85.81 M | 17.98 M | 353.26 K |
Reviva Pharmaceuticals Asset Utilization
One of the ways to look at asset utilization of Reviva is to check how much profit was generated for every dollar of assets it reports. Reviva Pharmaceuticals holds a negative application of assets of -3.28 pct., losing $0.0328 for each dollar of assets held by the company. Inadequate asset utilization implies the company is being less effective with each dollar of assets it holds. Put it differently, asset utilization of Reviva Pharmaceuticals Holdings shows how discouraging it operates for each dollar spent on its assets.Reviva Pharmaceuticals Profitability Analysis
Net Loss for the year was (39.26 M) with profit before overhead, payroll, taxes, and interest of 0.About Reviva Pharmaceuticals Valuation
Our relative valuation model uses a comparative analysis of Reviva Pharmaceuticals. We calculate exposure to Reviva Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Reviva Pharmaceuticals's related companies.Reviva Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops therapies to address unmet medical needs in the areas of central nervous system, cardiovascular, metabolic, and inflammatory diseases. Its lead product candidate is RP5063 for the treatment of schizophrenia, bipolar disorder, and major depressive disorder, as well as for treating pulmonary arterial hypertension and idiopathic pulmonary fibrosis. Reviva Pharmaceuticals is traded on NASDAQ Exchange in the United States.
Reviva Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as Reviva Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 23.8 M |
Additional Tools for Reviva Stock Analysis
When running Reviva Pharmaceuticals' price analysis, check to measure Reviva Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Reviva Pharmaceuticals is operating at the current time. Most of Reviva Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Reviva Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Reviva Pharmaceuticals' price. Additionally, you may evaluate how the addition of Reviva Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.